Moreover, silencing of C-FLIP had sensitized EGFR-mutant NSCLC to erlotinib and, conversely, its overexpression rescued EGFR-mutant lung cancer cells from erlotinib treatment, presumably through modulation of NF-κB activity (112). This evidence concerns the gene EGFR and lung carcinoma.